MSB 0.52% 95.0¢ mesoblast limited

Today's press release smacks of an impending RMAT designation...

  1. 522 Posts.
    lightbulb Created with Sketch. 3626
    Today's press release smacks of an impending RMAT designation for CHF in both advanced and end-stage CHF.
    Meaning conditional approval and hence the words " .....accelerated entry of this product candidate into the market..."

    The FDA, in its RMAT designation eligibility clearly states the following as one of the conditions:
    "Preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition"

    In other news, Mallinckrodt coughed up $80 million to acquire Infacare.
    I am expecting (hopefully more) for MSB's GvHD:
    http://www.mallinckrodt.com/about/news-and-media/2291927
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
-0.005(0.52%)
Mkt cap ! $1.084B
Open High Low Value Volume
96.0¢ 98.5¢ 91.5¢ $4.743M 4.999M

Buyers (Bids)

No. Vol. Price($)
3 123302 95.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.5¢ 314 1
View Market Depth
Last trade - 16.10pm 29/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.